210 related articles for article (PubMed ID: 37924098)
1. Comprehensive analysis of alternative splicing across multiple transcriptomic cohorts reveals prognostic signatures in prostate cancer.
Mou Z; Spencer J; McGrath JS; Harries LW
Hum Genomics; 2023 Nov; 17(1):97. PubMed ID: 37924098
[TBL] [Abstract][Full Text] [Related]
2. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
3. Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy.
Su Q; Liu Z; Chen C; Gao H; Zhu Y; Wang L; Pan M; Liu J; Yang X; Tian J
Cancer Med; 2021 Sep; 10(18):6492-6502. PubMed ID: 34453418
[TBL] [Abstract][Full Text] [Related]
4. A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer.
Rade M; Kreuz M; Borkowetz A; Sommer U; Blumert C; Füssel S; Bertram C; Löffler D; Otto DJ; Wöller LA; Schimmelpfennig C; Köhl U; Gottschling AC; Hönscheid P; Baretton GB; Wirth M; Thomas C; Horn F; Reiche K
Mol Med; 2024 Feb; 30(1):19. PubMed ID: 38302875
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated fibroblast-derived gene signatures predict radiotherapeutic survival in prostate cancer patients.
Zhang R; Liu F
J Transl Med; 2022 Oct; 20(1):453. PubMed ID: 36195908
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract][Full Text] [Related]
7. Comprehensively analysis of splicing factors to construct prognosis prediction classifier in prostate cancer.
Zhang H; Tian J; Ren S; Han B; Tian R; Zuo X; Liu H; Wang Z; Cui Y; Liu L; Guo H; Zhang F; Niu R
J Cell Mol Med; 2023 Sep; 27(18):2684-2700. PubMed ID: 37559353
[TBL] [Abstract][Full Text] [Related]
8. Systematic profiling of alternative splicing signature reveals prognostic predictor for prostate cancer.
Zhao J; Chang L; Gu X; Liu J; Sun B; Wei X
Cancer Sci; 2020 Aug; 111(8):3020-3031. PubMed ID: 32530556
[TBL] [Abstract][Full Text] [Related]
9. A novel 13 RNA binding proteins (RBPs) signature could predict prostate cancer biochemical recurrence.
Xing Q; Liu S; Luan J; Wang Y; Ma L
Pathol Res Pract; 2021 Sep; 225():153587. PubMed ID: 34419719
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a set of novel and robust 4-lncRNA-based nomogram predicting prostate cancer survival by bioinformatics analysis.
Zhang P; Tan X; Zhang D; Gong Q; Zhang X
PLoS One; 2021; 16(5):e0249951. PubMed ID: 33945533
[TBL] [Abstract][Full Text] [Related]
11. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
12. Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer.
Alshalalfa M; Schliekelman M; Shin H; Erho N; Davicioni E
Biol Cell; 2015 Jul; 107(7):232-44. PubMed ID: 25900404
[TBL] [Abstract][Full Text] [Related]
13. Gene signatures ESC, MYC and ERG-fusion are early markers of a potentially dangerous subtype of prostate cancer.
Rye MB; Bertilsson H; Drabløs F; Angelsen A; Bathen TF; Tessem MB
BMC Med Genomics; 2014 Aug; 7():50. PubMed ID: 25115192
[TBL] [Abstract][Full Text] [Related]
14. Circular RNAs and Their Linear Transcripts as Diagnostic and Prognostic Tissue Biomarkers in Prostate Cancer after Prostatectomy in Combination with Clinicopathological Factors.
Rochow H; Jung M; Weickmann S; Ralla B; Stephan C; Elezkurtaj S; Kilic E; Zhao Z; Jung K; Fendler A; Franz A
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33105568
[TBL] [Abstract][Full Text] [Related]
15. Autophagy-related circRNA evaluation reveals hsa_circ_0001747 as a potential favorable prognostic factor for biochemical recurrence in patients with prostate cancer.
Zhong C; Wu K; Wang S; Long Z; Yang T; Zhong W; Tan X; Wang Z; Li C; Lu J; Mao X
Cell Death Dis; 2021 Jul; 12(8):726. PubMed ID: 34294687
[TBL] [Abstract][Full Text] [Related]
16. Alternative splicing of NF-YA promotes prostate cancer aggressiveness and represents a new molecular marker for clinical stratification of patients.
Belluti S; Semeghini V; Rigillo G; Ronzio M; Benati D; Torricelli F; Reggiani Bonetti L; Carnevale G; Grisendi G; Ciarrocchi A; Dominici M; Recchia A; Dolfini D; Imbriano C
J Exp Clin Cancer Res; 2021 Nov; 40(1):362. PubMed ID: 34782004
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of an Individualized Immune Prognostic Signature for Recurrent Prostate Cancer.
Jin Y; Wang L; Lou H; Song C; He X; Ding M
Comb Chem High Throughput Screen; 2021; 24(1):98-108. PubMed ID: 32593277
[TBL] [Abstract][Full Text] [Related]
18. Biochemical recurrence related metabolic novel signature associates with immunity and ADT treatment responses in prostate cancer.
Wang X; Lv Z; Xia H; Guo X; Wang J; Wang J; Liu M
Cancer Med; 2023 Jan; 12(1):862-878. PubMed ID: 35681277
[TBL] [Abstract][Full Text] [Related]
19. Classification of pyroptosis patterns and construction of a novel prognostic model for prostate cancer based on bulk and single-cell RNA sequencing.
Fu J; Li G; Luo R; Lu Z; Wang Y
Front Endocrinol (Lausanne); 2022; 13():1003594. PubMed ID: 36105400
[TBL] [Abstract][Full Text] [Related]
20. Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.
Gerke JS; Orth MF; Tolkach Y; Romero-Pérez L; Wehweck FS; Stein S; Musa J; Knott MML; Hölting TLB; Li J; Sannino G; Marchetto A; Ohmura S; Cidre-Aranaz F; Müller-Nurasyid M; Strauch K; Stief C; Kristiansen G; Kirchner T; Buchner A; Grünewald TGP
Int J Cancer; 2020 Apr; 146(7):2036-2046. PubMed ID: 31732966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
